Regeneron’s Met bet falls short
The Met x Met ADC REGN5093-M114 has been discontinued, but a Met x Met bispecific antibody remains.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
ASCO-GU – Pfizer looks for bigger bladder cancer invasion
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
